Lumasiran - Latest Advances

Class-Specific Adverse Events of Patients Treated with Small Interfering RNA Therapeutics: A Disproportionality Analysis of the United States Food and Drug Administration Adverse Event Reporting System Database Based on the MY FAERS Platform.

Journal: Nucleic acid therapeutics

Published: November 22, 2025

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.

Journal: Frontiers in pharmacology

Published: October 07, 2025

RNA interference medication and transplantation procedures in patients with primary hyperoxaluria type 1 (PH1).

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: October 03, 2025

Long-term Lumasiran Therapy Final Results from a Phase 2 Open-label Extension Study in Primary Hyperoxaluria.

Journal: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

Published: September 22, 2025

Administration of lumasiran in a child with infantile oxalosis undergoing chronic peritoneal dialysis: A case report

Journal: Nephrologie & therapeutique

Published: June 11, 2025

Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1.

Journal: Clinical journal of the American Society of Nephrology : CJASN

Published: May 14, 2025

Fine-tuning circulating oxalate levels to improve transplant strategies in primary hyperoxaluria: what is the ideal threshold in pediatrics?

Journal: Nephrologie & therapeutique

Published: March 11, 2025

Primary Hyperoxaluria Type 1: An Unexpected Diagnosis after Kidney Transplantation.

Journal: Kidney & blood pressure research

Published: March 09, 2025

The evolving role of liver transplantation as enzyme replacement therapy in the era of RNA nanotherapies.

Journal: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

Published: March 06, 2025

Plasma Glycolate Levels Contribute to Drive the Decision of Isolated Kidney Transplantation in Dialyzed Patients with End-Stage Kidney Disease due to Primary Hyperoxaluria Type 1 Treated with Lumasiran: A Case Report.

Journal: Case reports in nephrology and dialysis

Published: February 04, 2025

Development, opportunities, and challenges of siRNA nucleic acid drugs.

Journal: Molecular therapy. Nucleic acids

Published: February 03, 2025

Lumasiran at birth changes the trajectory of primary hyperoxaluria type 1: same disease, different outcomes in two affected siblings.

Journal: Journal of nephrology

Published: January 17, 2025

Filters

Class-Specific Adverse Events of Patients Treated with Small Interfering RNA Therapeutics: A Disproportionality Analysis of the United States Food and Drug Administration Adverse Event Reporting System Database Based on the MY FAERS Platform.

Class-Specific Adverse Events of Patients Treated with Small Interfering RNA Therapeutics: A Disproportionality Analysis of the United States Food and Drug Administration Adverse Event Reporting System Database Based on the MY FAERS Platform.

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.

RNA interference medication and transplantation procedures in patients with primary hyperoxaluria type 1 (PH1).

RNA interference medication and transplantation procedures in patients with primary hyperoxaluria type 1 (PH1).

Long-term Lumasiran Therapy Final Results from a Phase 2 Open-label Extension Study in Primary Hyperoxaluria.

Long-term Lumasiran Therapy Final Results from a Phase 2 Open-label Extension Study in Primary Hyperoxaluria.

Administration of lumasiran in a child with infantile oxalosis undergoing chronic peritoneal dialysis: A case report

Administration of lumasiran in a child with infantile oxalosis undergoing chronic peritoneal dialysis: A case report

Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1.

Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1.

Fine-tuning circulating oxalate levels to improve transplant strategies in primary hyperoxaluria: what is the ideal threshold in pediatrics?

Fine-tuning circulating oxalate levels to improve transplant strategies in primary hyperoxaluria: what is the ideal threshold in pediatrics?

Primary Hyperoxaluria Type 1: An Unexpected Diagnosis after Kidney Transplantation.

Primary Hyperoxaluria Type 1: An Unexpected Diagnosis after Kidney Transplantation.

The evolving role of liver transplantation as enzyme replacement therapy in the era of RNA nanotherapies.

The evolving role of liver transplantation as enzyme replacement therapy in the era of RNA nanotherapies.

Plasma Glycolate Levels Contribute to Drive the Decision of Isolated Kidney Transplantation in Dialyzed Patients with End-Stage Kidney Disease due to Primary Hyperoxaluria Type 1 Treated with Lumasiran: A Case Report.

Plasma Glycolate Levels Contribute to Drive the Decision of Isolated Kidney Transplantation in Dialyzed Patients with End-Stage Kidney Disease due to Primary Hyperoxaluria Type 1 Treated with Lumasiran: A Case Report.

Development, opportunities, and challenges of siRNA nucleic acid drugs.

Development, opportunities, and challenges of siRNA nucleic acid drugs.

Lumasiran at birth changes the trajectory of primary hyperoxaluria type 1: same disease, different outcomes in two affected siblings.

Lumasiran at birth changes the trajectory of primary hyperoxaluria type 1: same disease, different outcomes in two affected siblings.